Plasma cell leukemia: from biology to treatment

European Journal of Haematology
Tomas JelinekR Hajek

Abstract

Plasma cell leukemia (PCL) is a very aggressive and rare form of malignant monoclonal gammopathy characterized by the presence of plasmocytes in peripheral blood. It is classified as primary PCL occuring 'de novo', or as secondary PCL in patients with relapsed/refractory multiple myeloma. Primary PCL is a distinct clinicopathological entity from myeloma with different cytogenetic abnormalities and molecular findings, which are usually found only in advanced multiple myeloma. The clinical course is aggressive with short remissions and reduced overall survival. The diagnostic criteria are based on the percentage (>20%) and absolute number (2 × 10(9) /L) of plasma cells in peripheral blood. After establishing diagnosis, induction therapy should begin promptly which is aimed to rapid disease control and to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens, followed by high-dose therapy with autologous stem cell transplantation, are recommended. Allogeneic transplantation can be considered in younger patients. This article reviews recent knowledge of this hematological malignancy that is associated with a very poor prognosis.

References

Dec 1, 1987·The American Journal of Medicine·P Noel, R A Kyle
May 1, 1974·Archives of Internal Medicine·R A KyleE D Bayrd
Dec 1, 1994·British Journal of Haematology·M A DimopoulosR Alexanian
Jan 8, 2000·Hematology/oncology Clinics of North America·J Bladé, R A Kyle
Apr 3, 2003·British Journal of Haematology·Jeroen E J GuikemaNicolaas A Bos
Mar 3, 2004·Cancer Research·Rafael FonsecaHerve Avet-Loiseau
Dec 21, 2004·International Journal of Cancer. Journal International Du Cancer·Azucena Esparís-OgandoJesús F San Miguel
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaji KumarThomas E Witzig
Aug 30, 2006·American Journal of Clinical Pathology·Terry K MorganYasodha Natkunam
Jan 12, 2007·Leukemia·W J ChngR Fonseca
May 1, 2007·Cancer·Pellegrino MustoUNKNOWN GIMEMA Cooperative Group
Sep 15, 2007·British Journal of Haematology·Hong ChangWei Xu
Nov 27, 2007·Nature Clinical Practice. Oncology·Stelvio BallantiAntonio Tabilio
Dec 8, 2007·Cancer Causes & Control : CCC·Jennifer F Yamamoto, Marc T Goodman
Jan 25, 2008·Leukemia·R E TiedemannR Fonseca
Feb 13, 2008·Haematologica·Andy C RawstronUNKNOWN European Myeloma Network
May 20, 2008·Medical Oncology·Milica ColovićSnezana Janković
May 30, 2009·Leukemia Research·Attilio OlivieriRosa Anna Cifarelli
Dec 10, 2009·Haematologica·Laura ChiecchioUNKNOWN UK Myeloma Forum
May 6, 2010·Haematologica·Mary B DrakeUNKNOWN European Group for Blood and Marrow Transplantation and the European Leukemia Net
Feb 8, 2011·Blood Reviews·Flavio Albarracin, Rafael Fonseca
Apr 29, 2011·Folia Histochemica Et Cytobiologica·Maria KrajBarbara Kruk

❮ Previous
Next ❯

Citations

Aug 13, 2015·International Journal of Molecular Sciences·Vittorio SimeonPellegrino Musto
Nov 1, 2016·Expert Review of Hematology·Antonino NeriPellegrino Musto
Nov 8, 2016·Leukemia & Lymphoma·Roberto MinaAntonio Palumbo
Apr 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pellegrino Musto
Mar 25, 2019·Expert Review of Hematology·Pellegrino MustoFiorella D'Auria
Jul 26, 2016·Oncology Letters·Nicoletta CoccaroFrancesco Albano
Oct 20, 2019·Annals of Hematology·Ella WillenbacherBrigitte Kircher
Feb 14, 2020·Cancers·Vanessa PintoM Helena Vasconcelos
Mar 21, 2016·Current Treatment Options in Oncology·Pellegrino MustoAntonino Neri
Jan 10, 2018·British Journal of Haematology·Artur JurczyszynJorge J Castillo
Sep 20, 2019·Clinical Case Reports·Sam NguAlexander Bershadskiy
Nov 30, 2019·Leukemia·Manisha BhutaniSaad Z Usmani
Jul 12, 2018·Oxford Medical Case Reports·Øyvind BruserudHåkon Reikvam
Mar 28, 2020·Palliative Care and Social Practice·Sarah Anne Bird, Kevin Boyd

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.